Trial drug helps children with deadly neuroblastoma

In a study of 226 children, Yu found that combining the antibody with other immune therapies cuts the risk of relapse by 20%.(…) Two years after getting the new therapy, 66% of kids were relapse-free, compared to 46% of kids randomly assigned to receive a standard therapy called retinoic acid, according to a study released Thursday, in advance of the annual meeting of the American Society of Clinical Oncology, which begins in two weeks in Orlando.”